
Opinion|Videos|March 13, 2025
TAR-200 Clinical Development Program in NMIBC
Experts briefly mention other ongoing phase 3 studies investigating TAR-200 for the treatment of non–muscle-invasive bladder cancer (NMIBC).
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you briefly mention other ongoing phase 3 studies with TAR-200?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Unmet needs and emerging solutions in MRI-guided prostate cancer care
2
HHS requests testosterone therapy label updates, citing new safety data
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC
5













